Probiotic potential of Lactobacillus agilis against oxidative, inflammatory and diabetic stresses

Abstract

Nutrients lacking diet is responsible for major health problems like obesity, heart diseases, cancer, diabetes and inflammation. Microbial nutraceuticals can be the best alternative to resolve the drawbacks related to the phytochemical-based production of nutraceuticals. In vivo study was designed using mice to assess the anti-diabetic, antioxidant and anti-inflammatory potential of Lactobacillus agilis (L. agilis). Mice were put in control, toxic, standard and L. agilis dose-treated groups. The diabetics, oxidative stress and inflammation (in paw) were induced in mice. In alloxan-treated mice, the blood sugar level was elevated to 600 mg/dL and then it was decreased to 190 mg/dL after the L. agilis dose. Weight gain was increased from 51.48% to 68.56% in groups of diabetic and oxidatively stressed mice respectively as compared to the probiotic (L. agilis dose) group (25.99%) and standard drug-treated mice group (29.35%). The effect of L. agilis dose treatment on the alloxan-induced liver injury presented normal histology of hepatic cells with a well-preserved nucleus, cytoplasm, and hepatocytes in L. agilis dose group of mice. Antioxidant enzymes in L. agilis treated mice group were significantly improved as compared to alloxan treated mice with values 22.1 ± 0.18 μg/mg (super oxide dismutase), 8.9 ± 0.12 μg/mg (catalase), 4.1 ± 0.12 μg/mg (glutathione) and 20.8 ± 0.4 μg/mg (SOD), 7.2 ± 0.1 μg/mg (CAT), 3.7 ± 0.14 μg/mg (GSH) respectively. Paw size (thickness) of the treated mice was significantly reduced at T4 in mice group (L. agilis 1 mL dose) with value 2.1 ± 0.12 cm. Current in vivo study presented probiotic potential of L. agilis that can be used as nutraceutical.

Keywords

• Lactobacillus agilis
• Mouse Modules
• Stresses
• Probiotic